Related Experiment Videos
Lithium augmentation for treatment-resistant depression in the elderly
J Lafferman1, K Solomon, P Ruskin
1Department of Psychiatry, Lockraven VA Medical Center, Baltimore, MD 21218.
Journal of Geriatric Psychiatry and Neurology
|January 1, 1988
Summary
Lithium augmentation effectively treated refractory depression in elderly patients unresponsive to standard therapies. While side effects occurred, dosage adjustments often managed them, showing promise for geriatric mental health.
Area of Science:
- Geriatric Psychiatry
- Pharmacology
- Neuroscience
Background:
- Lithium is an established mood stabilizer and augmentation agent for various psychiatric medications.
- Refractory depression in the elderly presents a significant clinical challenge with limited treatment options.
Observation:
- This study investigated the safety and efficacy of lithium augmentation in 14 elderly patients with treatment-resistant depression.
- Patients had not responded adequately to or could not tolerate standard antidepressant therapies.
Findings:
- Seven out of 14 elderly patients achieved complete remission of depressive symptoms.
- Three patients experienced a partial response to lithium augmentation.
- Side effects such as peripheral weakness, tremor, and neurotoxicity led to discontinuation in three patients, while two others tolerated adjusted lower dosages.
Implications:
- Lithium augmentation represents a viable and promising therapeutic strategy for geriatric patients with refractory depression.
- Careful monitoring and dosage titration are crucial for managing potential side effects in this population.
- Further research is warranted to optimize lithium augmentation protocols for elderly individuals with treatment-resistant depression.